Jane Larkindale serves as the Vice President of Clinical Science at PepGen, where she leverages her extensive expertise in rare disease drug development to drive innovative solutions for patients with neuromuscular disorders. With a robust background in science, business, and communications, Jane is uniquely positioned...
Jane Larkindale serves as the Vice President of Clinical Science at PepGen, where she leverages her extensive expertise in rare disease drug development to drive innovative solutions for patients with neuromuscular disorders. With a robust background in science, business, and communications, Jane is uniquely positioned to bridge the gap between complex scientific research and practical clinical applications. Her current role involves leading a pivotal translational and clinical program focused on myotonic dystrophy, where she is responsible for designing clinical trials and interpreting data for first-in-human and Phase 2 studies of groundbreaking therapies targeting Duchenne muscular dystrophy and myotonic dystrophy.
Jane's leadership extends to the development of endpoint and biomarker strategies for these lead programs, ensuring that the clinical trials are not only scientifically rigorous but also aligned with regulatory requirements. Her deep understanding of disease models and regulatory submissions enables her to navigate the complexities of rare disease drug development effectively. With a proven track record of advancing programs from preclinical stages through to successful clinical milestones, Jane is committed to translating scientific discoveries into viable treatment options for patients. Her communication skills play a crucial role in fostering collaboration among cross-functional teams, ensuring that all stakeholders are aligned on project goals and timelines. As a thought leader in the field, Jane continues to contribute to the advancement of therapies that have the potential to transform the lives of individuals affected by rare neuromuscular diseases.
